Wen-Chien Cheng1,2,3, Wei-Chih Liao1,3,4, Biing-Ru Wu1,2, Chih-Yu Chen1,3,4, Meng-Fang Shen1, Wei-Chun Chen1,3,4, Te-Chun Hsia1,3,5, Chih-Yen Tu1,2,6, Chia-Hung Chen1,4,7, Wu-Huei Hsu1. 1. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, Taichung. 2. School of Medicine, China Medical University, Taichung. 3. Department of Internal Medicine, Hyperbaric Oxygen Therapy Center, China Medical University, Taichung. 4. Graduate Institute of Clinical Medical Science, China Medical University, Taichung. 5. Department of Respiratory Therapy, China Medical University, Taichung. 6. Department of Life Science, National Chung Hsing University, Taichung. 7. Taiwan Clinical Trial Consortium for Lung Diseases (TCoC), Taichung.
Abstract
BACKGROUND: According to several phase III studies, tiotropium [a long-acting muscarinic antagonist (LAMA)] is a well-tolerated add-on therapy to inhaled corticosteroids (ICS) for asthmatics with or without the addition of long-acting beta2-agonists (LABAs). However, real-world studies based on clinical phenotypes to predict the long-term need of tiotropium as an add-on therapy for asthmatics are limited. METHODS: This is a retrospective study conducted at a single medical center in Taiwan from July 2016 to July 2018. An asthma control test (ACT) is applied to uncontrolled asthmatics to evaluate the effectiveness of tiotropium as an add-on therapy. Asthmatic subgroups with different clinical phenotypes and needing long-term tiotropium as a maintenance treatment are identified. The effectiveness of tiotropium add-on therapy is defined as an improvement of ACT score ≥3 points 3 months after the treatment (vs. baseline), while the long-term requirement of tiotropium is defined as tiotropium dependency >1 year. RESULTS: The study analyzed a total of 160 uncontrolled asthmatics regardless of low- or medium-to-high-dose ICS plus LABA. One hundred and twelve patients responded well (ACT score increased ≥3 points) to tiotropium. These patients were further divided into two subgroups: one with tiotropium add-on therapy for ≥1 year due to patients' difficulties in stepping down from tiotropium; the other with tiotropium add-on therapy for <1 year due to successful step-down treatment according to Global Initiative for Asthma (GINA) score. All clinical characteristics of these two groups were collected and analyzed. Univariate and multivariate analyses showed that asthma-and-chronic obstructive pulmonary disease (COPD)-overlap (ACO), initial forced expiratory volume-one second (FEV1) % predicted <80%, or body mass index (BMI) >30 kg/m2 were predictors for asthmatics requiring long-term tiotropium add-on therapy. CONCLUSIONS: Tiotropium add-on therapy is effective for uncontrolled asthmatics. Moreover, patients with ACO, initial FEV1% predicted <80%, or BMI >30 kg/m2 require long-term tiotropium add-on therapy for asthma control. 2019 Journal of Thoracic Disease. All rights reserved.
BACKGROUND: According to several phase III studies, tiotropium [a long-acting muscarinic antagonist (LAMA)] is a well-tolerated add-on therapy to inhaled corticosteroids (ICS) for asthmatics with or without the addition of long-acting beta2-agonists (LABAs). However, real-world studies based on clinical phenotypes to predict the long-term need of tiotropium as an add-on therapy for asthmatics are limited. METHODS: This is a retrospective study conducted at a single medical center in Taiwan from July 2016 to July 2018. An asthma control test (ACT) is applied to uncontrolled asthmatics to evaluate the effectiveness of tiotropium as an add-on therapy. Asthmatic subgroups with different clinical phenotypes and needing long-term tiotropium as a maintenance treatment are identified. The effectiveness of tiotropium add-on therapy is defined as an improvement of ACT score ≥3 points 3 months after the treatment (vs. baseline), while the long-term requirement of tiotropium is defined as tiotropium dependency >1 year. RESULTS: The study analyzed a total of 160 uncontrolled asthmatics regardless of low- or medium-to-high-dose ICS plus LABA. One hundred and twelve patients responded well (ACT score increased ≥3 points) to tiotropium. These patients were further divided into two subgroups: one with tiotropium add-on therapy for ≥1 year due to patients' difficulties in stepping down from tiotropium; the other with tiotropium add-on therapy for <1 year due to successful step-down treatment according to Global Initiative for Asthma (GINA) score. All clinical characteristics of these two groups were collected and analyzed. Univariate and multivariate analyses showed that asthma-and-chronic obstructive pulmonary disease (COPD)-overlap (ACO), initial forced expiratory volume-one second (FEV1) % predicted <80%, or body mass index (BMI) >30 kg/m2 were predictors for asthmatics requiring long-term tiotropium add-on therapy. CONCLUSIONS: Tiotropium add-on therapy is effective for uncontrolled asthmatics. Moreover, patients with ACO, initial FEV1% predicted <80%, or BMI >30 kg/m2 require long-term tiotropium add-on therapy for asthma control. 2019 Journal of Thoracic Disease. All rights reserved.
Entities:
Keywords:
Asthma control test (ACT); Global Initiative for Asthma (GINA); clinical predictors; symptomatic asthma; tiotropium add-on therapy
Authors: A Dijkstra; J M Vonk; H Jongepier; G H Koppelman; J P Schouten; N H T ten Hacken; W Timens; D S Postma Journal: Thorax Date: 2005-11-24 Impact factor: 9.139
Authors: Huib A M Kerstjens; Michael Engel; Ronald Dahl; Pierluigi Paggiaro; Ekkehard Beck; Mark Vandewalker; Ralf Sigmund; Wolfgang Seibold; Petra Moroni-Zentgraf; Eric D Bateman Journal: N Engl J Med Date: 2012-09-02 Impact factor: 91.245
Authors: Thomas B Casale; Eric D Bateman; Mark Vandewalker; J Christian Virchow; Hendrik Schmidt; Michael Engel; Petra Moroni-Zentgraf; Huib A M Kerstjens Journal: J Allergy Clin Immunol Pract Date: 2017-11-22
Authors: Eckard Hamelmann; Eric D Bateman; Christian Vogelberg; Stanley J Szefler; Mark Vandewalker; Petra Moroni-Zentgraf; Mandy Avis; Anna Unseld; Michael Engel; Attilio L Boner Journal: J Allergy Clin Immunol Date: 2016-03-05 Impact factor: 10.793
Authors: Anne E Dixon; Richard E Pratley; Patrick M Forgione; David A Kaminsky; Laurie A Whittaker-Leclair; Laurianne A Griffes; Jayanthi Garudathri; Danielle Raymond; Mathew E Poynter; Janice Y Bunn; Charles G Irvin Journal: J Allergy Clin Immunol Date: 2011-07-23 Impact factor: 10.793
Authors: Robert A Nathan; Christine A Sorkness; Mark Kosinski; Michael Schatz; James T Li; Philip Marcus; John J Murray; Trudy B Pendergraft Journal: J Allergy Clin Immunol Date: 2004-01 Impact factor: 10.793
Authors: Donald P Tashkin; Bartolome Celli; Stephen Senn; Deborah Burkhart; Steven Kesten; Shailendra Menjoge; Marc Decramer Journal: N Engl J Med Date: 2008-10-05 Impact factor: 91.245
Authors: Christian Vogelberg; Petra Moroni-Zentgraf; Migle Leonaviciute-Klimantaviciene; Ralf Sigmund; Eckard Hamelmann; Michael Engel; Stanley Szefler Journal: Respir Res Date: 2015-02-07